Recent studies have shown that anti-CLL activity of autologous CAR-T cells is improved when they are administered in combination with the BTK inhibitors ibrutinib or acalabrutinib [286,287] due to their ability to increase T cell number and function in CLL [288]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.